Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Erica B Bhavsar"'
Autor:
Toby A. Eyre, John N. Allan, Bruce D. Cheson, Kayla Bigelow, Colleen Dorsey, Andrew D. Zelenetz, Amber C. King, Julie M. Goodfriend, Chadi Nabhan, Hanna B. Weissbrot, Jason C. Lee, Neil Bailey, Erica B. Bhavsar, Talha Munir, Nicolas Martinez-Calle, Christopher P. Fox, Thomas D. Rodgers, Stephen J. Schuster, Timothy J. Voorhees, Kentson Lam, Rachael Pocock, Othman S. Akhtar, Pratik Shah, Krista M. Isaac, Ariel F. Grajales-Cruz, Sirin Khajavian, Andrea Sitlinger, Allison M. Winter, Kate J. Whitaker, Christine A. Garcia, Helen Parry, Craig A. Portell, Paul M. Barr, Joanna Rhodes, Catherine C. Coombs, Michael Choi, Bita Fakhri, Satyen Gohil, John M. Pagel, Jeffrey J. Pu, Pallawi Torka, Alan P. Skarbnik, Jacqueline Barrientos, Javier A. Pinilla-Ibarz, Guilherme Fleury Perini, Maryam Sarraf Yazdy, Chaitra S. Ujjani, Mazyar Shadman, Danielle Brander, Nicole Lamanna, Brian T. Hill, Ryan Jacobs, Lindsey E. Roeker, Anthony R. Mato
Purpose:Venetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following venetoclax discontinuation remains nonstandard and poorly understood.Experimental Des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e72e05cfed97bbc9e2e47db93b397aae
https://doi.org/10.1158/1078-0432.c.6528851
https://doi.org/10.1158/1078-0432.c.6528851
Autor:
Toby A. Eyre, John N. Allan, Bruce D. Cheson, Kayla Bigelow, Colleen Dorsey, Andrew D. Zelenetz, Amber C. King, Julie M. Goodfriend, Chadi Nabhan, Hanna B. Weissbrot, Jason C. Lee, Neil Bailey, Erica B. Bhavsar, Talha Munir, Nicolas Martinez-Calle, Christopher P. Fox, Thomas D. Rodgers, Stephen J. Schuster, Timothy J. Voorhees, Kentson Lam, Rachael Pocock, Othman S. Akhtar, Pratik Shah, Krista M. Isaac, Ariel F. Grajales-Cruz, Sirin Khajavian, Andrea Sitlinger, Allison M. Winter, Kate J. Whitaker, Christine A. Garcia, Helen Parry, Craig A. Portell, Paul M. Barr, Joanna Rhodes, Catherine C. Coombs, Michael Choi, Bita Fakhri, Satyen Gohil, John M. Pagel, Jeffrey J. Pu, Pallawi Torka, Alan P. Skarbnik, Jacqueline Barrientos, Javier A. Pinilla-Ibarz, Guilherme Fleury Perini, Maryam Sarraf Yazdy, Chaitra S. Ujjani, Mazyar Shadman, Danielle Brander, Nicole Lamanna, Brian T. Hill, Ryan Jacobs, Lindsey E. Roeker, Anthony R. Mato
Supplemental Figure 2: Progression free survival of patients without prior BTKi exposure who had progressed on venetoclax and were then treated with BTKi.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::391825ca38ac12df33b7f05e19ba469f
https://doi.org/10.1158/1078-0432.22474643.v1
https://doi.org/10.1158/1078-0432.22474643.v1
Autor:
Toby A. Eyre, John N. Allan, Bruce D. Cheson, Kayla Bigelow, Colleen Dorsey, Andrew D. Zelenetz, Amber C. King, Julie M. Goodfriend, Chadi Nabhan, Hanna B. Weissbrot, Jason C. Lee, Neil Bailey, Erica B. Bhavsar, Talha Munir, Nicolas Martinez-Calle, Christopher P. Fox, Thomas D. Rodgers, Stephen J. Schuster, Timothy J. Voorhees, Kentson Lam, Rachael Pocock, Othman S. Akhtar, Pratik Shah, Krista M. Isaac, Ariel F. Grajales-Cruz, Sirin Khajavian, Andrea Sitlinger, Allison M. Winter, Kate J. Whitaker, Christine A. Garcia, Helen Parry, Craig A. Portell, Paul M. Barr, Joanna Rhodes, Catherine C. Coombs, Michael Choi, Bita Fakhri, Satyen Gohil, John M. Pagel, Jeffrey J. Pu, Pallawi Torka, Alan P. Skarbnik, Jacqueline Barrientos, Javier A. Pinilla-Ibarz, Guilherme Fleury Perini, Maryam Sarraf Yazdy, Chaitra S. Ujjani, Mazyar Shadman, Danielle Brander, Nicole Lamanna, Brian T. Hill, Ryan Jacobs, Lindsey E. Roeker, Anthony R. Mato
Supplemental Figure 1: Overall survival of entire cohort from initiation of venetoclax.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48f28a1d557f9e1d57cd60895ef876dc
https://doi.org/10.1158/1078-0432.22474646.v1
https://doi.org/10.1158/1078-0432.22474646.v1
Autor:
Rachel B. Darman, Michael Seiler, Anant A. Agrawal, Kian H. Lim, Shouyong Peng, Daniel Aird, Suzanna L. Bailey, Erica B. Bhavsar, Betty Chan, Simona Colla, Laura Corson, Jacob Feala, Peter Fekkes, Kana Ichikawa, Gregg F. Keaney, Linda Lee, Pavan Kumar, Kaiko Kunii, Crystal MacKenzie, Mark Matijevic, Yoshiharu Mizui, Khin Myint, Eun Sun Park, Xiaoling Puyang, Anand Selvaraj, Michael P. Thomas, Jennifer Tsai, John Y. Wang, Markus Warmuth, Hui Yang, Ping Zhu, Guillermo Garcia-Manero, Richard R. Furman, Lihua Yu, Peter G. Smith, Silvia Buonamici
Publikováno v:
Cell Reports, Vol 13, Iss 5, Pp 1033-1045 (2015)
Recurrent mutations in the spliceosome are observed in several human cancers, but their functional and therapeutic significance remains elusive. SF3B1, the most frequently mutated component of the spliceosome in cancer, is involved in the recognition
Externí odkaz:
https://doaj.org/article/ff6c0ceb5e1f4d5b93d3d3ccbbf6a31c
Autor:
Lindsey E Roeker, Lydia Scarfo, Thomas Chatzikonstantinou, Pau Abrisqueta, Toby A. Eyre, Raul Cordoba, Ana Muntañola Prat, Guillermo Villacampa, Lori A. Leslie, Michael Koropsak, Giulia Quaresmini, John N. Allan, Richard R. Furman, Erica B Bhavsar, John M. Pagel, Jose Angel Hernandez-Rivas, Krish Patel, Marina Motta, Neil Bailey, Fatima Miras, Nicole Lamanna, Rosalia Alonso, Santiago Osorio-Prendes, Candida Vitale, Manali Kamdar, Patricia Baltasar, Anders Österborg, Lotta Hanson, Mónica Baile, Ines Rodríguez-Hernández, Susana Valenciano, Viola Maria Popov, Abelardo Barez Garcia, Ana Alfayate, Ana C Oliveira, Barbara Eichhorst, Francesca M. Quaglia, Gianluigi Reda, Javier Lopez Jimenez, Marzia Varettoni, Monia Marchetti, Pilar Romero, Rosalía Riaza Grau, Talha Munir, Amaya Zabalza, Ann Janssens, Carsten U Niemann, Guilherme Fleury Perini, Julio Delgado, Lucrecia Yanez San Segundo, Ma Isabel Gómez Roncero, Matthew Wilson, Piers Patten, Roberto Marasca, Sunil Iyengar, Amanda Seddon, Ana Torres, Angela Ferrari, Carolina Cuéllar-García, Daniel Wojenski, Dima El-Sharkawi, Gilad Itchaki, Helen Parry, Juan José Mateos-Mazón, Nicolas Martinez-Calle, Shuo Ma, Daniel Naya, Ellen Van Der Spek, Erlene K. Seymour, Eva Gimeno Vázquez, Gian Matteo Rigolin, Francesca Romana Mauro, Harriet S Walter, Jorge Labrador, Lorenzo De Paoli, Luca Laurenti, Elena Ruiz, Mark-David Levin, Martin Šimkovič, Martin Špaček, Rafa Andreu, Renata Walewska, Sonia Perez-Gonzalez, Suchitra Sundaram, Adrian Wiestner, Amalia Cuesta, Angus Broom, Arnon P. Kater, Begoña Muiña, César A Velasquez, Chaitra S. Ujjani, Cristina Seri, Darko Antic, Dominique Bron, Elisabeth Vandenberghe, Elise A. Chong, Enrico Lista, Fiz Campoy García, Giovanni Del Poeta, Inhye Ahn, Jeffrey J. Pu, Jennifer R Brown, Juan Alfonso Soler Campos, Lara Malerba, Livio Trentin, Lorella Orsucci, Lucia Farina, Lucia Villalon, Maria Jesus Vidal, Maria Jose Sanchez, Maria Jose Terol, Maria Rosaria De Paolis, Massimo Gentile, Matthew S. Davids, Mazyar Shadman, Mohamed A Yassin, Myriam Foglietta, Ozren Jaksic, Paolo Sportoletti, Paul M. Barr, Rafael Ramos, Raquel Santiago, Rosa Ruchlemer, Sabina Kersting, Scott F. Huntington, Tobias Herold, Yair Herishanu, Meghan C. Thompson, Sonia Lebowitz, Christine Ryan, Ryan W. Jacobs, Craig A. Portell, Krista Isaac, Alessandro Rambaldi, Chadi Nabhan, Danielle M. Brander, Emili Montserrat, Giuseppe Rossi, Jose A. Garcia-Marco, Marta Coscia, Nikita Malakhov, Noemi Fernandez-Escalada, Sigrid Strand Skånland, Callie C. Coombs, Paola Ghione, Stephen J. Schuster, Robin Foà, Antonio Cuneo, Francesc Bosch, Kostas Stamatopoulos, Paolo Ghia, Anthony R. Mato, Meera Patel
Publikováno v:
Blood
Introduction: Patients (pts) with CLL may be at particular risk of severe COVID-19 given advanced age and immune dysregulation. Two large series with limited follow-up have reported outcomes for pts with CLL and COVID-19 (Scarfò, et al. Leukemia 202
Autor:
John N. Allan, Joseph Casano, Richard R. Furman, Erica B. Bhavsar, Susan Mathew, Julia T. Geyer, Attilio Orazi, Yen-Chun Liu, Elizabeth Margolskee
Publikováno v:
Modern Pathology. 33:344-353
TP53 alteration in chronic lymphocytic leukemia indicates a high-risk disease that is usually refractory to chemotherapy. It may be caused by deletion of 17p involving the loss of TP53 gene, which occurs in low percentage of patients at diagnosis but
Autor:
Federico Gaiti, Rafael C. Schulman, Chelston Ang, Ronan Chaligne, Adrian Wiestner, Nathaniel D. Omans, Anna S. Nam, Danny Luan, Richard R. Furman, Preeti Trisal, Gregory Mullokandov, Neville Dusaj, Joshua S. Schiffman, Erica B. Bhavsar, Franco Izzo, Andrew Lipsky, Shirley Chen, Anita Gandhi, Kyu-Tae Kim, Dan A. Landau, Chingiz Underbayev, Paulina Chamely, John N. Allan
Publikováno v:
Blood. 136:40-42
Mutations in the kinase binding domain of BTK at position C481 are associated with resistance to BTK inhibitor (BTKi) therapy in chronic lymphocytic leukemia (CLL). Nearly half of patients manifesting clinical progression with these alterations exhib
Autor:
Richard R. Furman, Ghaith Abu-Zeinah, Erica B. Bhavsar, John N. Allan, Daniel R. Helbig, Paul J. Christos
Publikováno v:
American Journal of Hematology. 96
Autor:
Alicia Alonso, Alessandro Pastore, Caroline Sheridan, Rafael C. Schulman, Joshua Felsenfeld, Ronan Chaligne, Kyu-Tae Kim, Kendell Clement, Evan Biederstedt, Federico Gaiti, Hongcang Gu, Dan A. Landau, Alexander Meissner, Lili Wang, Davide Risso, Erica B. Bhavsar, Catherine J. Wu, Andreas Gnirke, Ryan M. Brand, Martin J. Aryee, Richard R. Furman, John N. Allan, Kirill Grigorev, Kevin Y. Huang, Nathaniel D. Omans, Steven Kothen-Hill
Publikováno v:
Nature
Genetic and epigenetic intra-tumoral heterogeneity cooperate to shape the evolutionary course of cancer1. Chronic lymphocytic leukaemia (CLL) is a highly informative model for cancer evolution as it undergoes substantial genetic diversification and e
Autor:
Erica B. Bhavsar, Anthony R. Mato, Paul M. Barr, John M. Pagel, Ryan Jacobs, Chadi Nabhan, Jeffrey J. Pu, Joanna Rhodes, Nirav N. Shah, Clive S. Zent, Sasanka M. Handunnetti, Brian T. Hill, Alan P Skarbnik, Frederick Lansigan, Jakub Svoboda, John N. Allan, Chaitra S. Ujjani, Andre Goy, Hande H. Tuncer, Constantine S. Tam, Bruce D. Cheson, Stephen J. Schuster, Lindsey E. Roeker, Peter V. Pickens, Richard R. Furman, Danielle M. Brander, Alison R. Sehgal, Douglas F. Beach, Mazyar Shadman, Nicole Lamanna
Publikováno v:
Am J Hematol
Ibrutinib demonstrated superior response rates and survival for treatment-naïve chronic lymphocytic leukemia (CLL) patients in a pivotal study that excluded patients younger than 65 (